Form 4: Insmed CEO William Lewis Executes Stock Option and Sells Shares Under 10b5-1 Plan

Insmed's CEO, William Lewis, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan, while also reporting holdings through family trusts.

Summary

• William Lewis, the Chair and CEO of Insmed Inc., executed a stock option and sold shares of common stock on May 1, 2025.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan.
• Lewis exercised options to acquire 6,830 shares at a price of $10.85 per share.
• He then sold 2,629 shares at a weighted average price of $72.24 and 4,201 shares at a weighted average price of $72.78.
• Following these transactions, Lewis directly owns 334,186 shares of common stock.
• He also indirectly owns shares through the Katie Procter Dynasty Trust (233,924 shares) and the William Lewis Family Legacy Trust (50,500 shares).
• The stock options became exercisable based on a vesting schedule that began on the first anniversary of the grant date, with additional vesting every six months thereafter.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects routine transactions under a pre-arranged plan. There's no indication of positive or negative implications for the company's performance.

Positives

• The CEO's transactions are being conducted under a pre-arranged 10b5-1 trading plan, which can provide transparency and reduce concerns about insider trading.

Negatives

• The CEO is selling shares, which could be interpreted negatively by some investors, although it is part of a pre-planned strategy.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create short-term price volatility.

Future Outlook

There is no specific future outlook provided in this document.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to manage potential insider trading concerns. Investors often monitor these transactions for insights into management's perspective on the company's value.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The vesting schedule of the options (25% after one year, then 12.5% every six months) is a fairly standard vesting arrangement.
• The use of a 10b5-1 trading plan is a common practice among executives to sell shares in a pre-planned and transparent manner, similar to practices at companies like Pfizer or Amgen.

Stakeholder Impact

• Shareholders may react to the news of the CEO selling shares, although the existence of a 10b5-1 plan should mitigate concerns.
• Employees may be interested in the CEO's transactions as an indicator of company performance and management's confidence.

Key Dates

Keywords

Insmed, William Lewis, stock options, share sales, Form 4, 10b5-1 plan, executive compensation, insider trading, Katie Procter Dynasty Trust, William Lewis Family Legacy Trust